We are live on ! Find out more
KURA icon

Kura Oncology

152 hedge funds and large institutions have $1.11B invested in Kura Oncology in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $7.27M | Put options by funds: $1.35M

67% more funds holding in top 10

Funds holding in top 10: 35 (+2)

24% more capital invested

Capital invested by funds: $897M → $1.11B (+$217M)

14% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 22

10% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 49

3.8% more ownership

Funds ownership: 96.32%100.12% (+3.8%)

1% more funds holding

Funds holding: 151152 (+1)

Holders
152
Holders Change
+1
Holders Change %
+0.66%
% of All Funds
2.4%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.08%
New
25
Increased
54
Reduced
49
Closed
22
Calls
$7.27M
Puts
$1.35M
Net Calls
+$5.92M
Net Calls Change
-$136K
Name Holding Trade Value Shares
Change
Change in
Stake
Verition Fund Management
26
Verition Fund Management
Connecticut
$7.93M +$7.12M +493,138 New
Goldman Sachs
27
Goldman Sachs
New York
$7.74M +$2.53M +174,913 +57%
Charles Schwab
28
Charles Schwab
California
$7.68M +$177K +12,237 +3%
ACP
29
Acuta Capital Partners
California
$7.62M +$2.63M +182,085 +62%
Morgan Stanley
30
Morgan Stanley
New York
$7.15M +$5.22M +361,551 +434%
CS
31
Candriam SCA
Luxembourg
$7.05M -$6.77M -469,118 -52%
Axa
32
Axa
France
$5.98M +$806K +55,788 +18%
ACM
33
Alethea Capital Management
Washington
$5.75M +$3.93M +271,820 +317%
UBS AM
34
UBS AM
Illinois
$5.64M -$306K -21,219 -6%
IHAM
35
Integral Health Asset Management
New York
$5.42M +$3.64M +252,000 +296%
Renaissance Technologies
36
Renaissance Technologies
New York
$4.48M +$3.04M +210,700 +311%
BBA
37
Baker Bros. Advisors
New York
$4.41M -$429K -29,700 -10%
WP
38
Woodline Partners
California
$4.3M
Two Sigma Advisers
39
Two Sigma Advisers
New York
$4.29M -$2.28M -157,700 -37%
Adage Capital Partners
40
Adage Capital Partners
Massachusetts
$4.02M +$3.61M +250,000 New
Bank of America
41
Bank of America
North Carolina
$4M -$652K -45,140 -15%
LOAMS
42
Lombard Odier Asset Management (Switzerland)
Switzerland
$3.77M +$229K +15,875 +7%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$3.72M +$11.7K +812 +0.4%
AllianceBernstein
44
AllianceBernstein
Tennessee
$3.5M +$1.99M +137,851 +173%
UBS Group
45
UBS Group
Switzerland
$3.04M +$347K +24,012 +15%
Rafferty Asset Management
46
Rafferty Asset Management
New York
$2.91M -$403K -27,887 -13%
Millennium Management
47
Millennium Management
New York
$2.51M -$1.38M -95,765 -38%
Citadel Advisors
48
Citadel Advisors
Florida
$2.47M -$1.67M -115,417 -43%
HS
49
HighVista Strategies
Massachusetts
$2.38M +$949K +65,709 +80%
Two Sigma Investments
50
Two Sigma Investments
New York
$2.35M -$5.15M -356,554 -71%

KURA Hedge Fund Activity: Q1 2022 in Review

152 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2022, worth a combined $1.11B — up 24% from $897M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KURA positions and 22 closed out — a net gain of 3 holders — while 54 added to existing stakes and 49 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $42.1M. The largest seller was Fidelity Investments, cutting an estimated $79.6M.

  • 152 institutional investors held Kura Oncology (KURA) as of Q1 2022, up from 151 in Q4 2021.
  • Funds reported $1.11B of Kura Oncology stock for Q1 2022, up 24% quarter-over-quarter.
  • 25 funds opened new Kura Oncology positions in Q1 2022 and 22 closed out, a net change of +3 holders.
  • The largest Kura Oncology buyer in Q1 2022 was EcoR1 Capital, an estimated $42.1M added.
  • The largest Kura Oncology seller in Q1 2022 was Fidelity Investments, an estimated $79.6M sold.

Based on aggregated 13F filings for Q1 2022.